Inhibition of glioblastoma growth in a highly invasive nude mouse model can be achieved by targeting epidermal growth factor receptor but not vascular endothelial growth factor receptor-2

Clinical Cancer Research

Volumn 14, Issue 17, 2008, Pages 5447-5458

  Martens, Tobias ^a   Laabs, Yvonne ^a   Günther, Hauke S ^a   Kemming, Dirk ^a   Zhu, Zhenping ^b   Witte, Larry ^b   Hagel, Christian ^a   Westphal, Manfred ^a   Lamszus, Katrin ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; MONOCLONAL ANTIBODY DC101; VASCULOTROPIN RECEPTOR 2; MONOCLONAL ANTIBODY;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER INVASION; CELL PROLIFERATION; CONTROLLED STUDY; GENE AMPLIFICATION; GENE EXPRESSION; GLIOBLASTOMA; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMAGE ANALYSIS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; TREATMENT RESPONSE; TUMOR VOLUME; TUMOR XENOGRAFT; ADULT; AGED; ANIMAL; BRAIN TUMOR; DISEASE MODEL; DRUG ANTAGONISM; DRUG POTENTIATION; DRUG SCREENING; FEMALE; GENETICS; MALE; MIDDLE AGED; NEOVASCULARIZATION (PATHOLOGY);

ADULT; AGED; ANIMALS; ANTIBODIES, MONOCLONAL; BRAIN NEOPLASMS; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; FEMALE; GENE AMPLIFICATION; GLIOBLASTOMA; HUMANS; MALE; MICE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOVASCULARIZATION, PATHOLOGIC; RECEPTOR, EPIDERMAL GROWTH FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 53049092916     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-0147     Document Type: Article

References (48)

1. Horten BC, Basler GA, Shapiro WR. Xenograft of human malignant glial tumorsinto brains ofnudemice. A histopathological study. J Neuropathol Exp Neurol 1981;40:493-511.
2. Giannini C, Sarkaria JN, Saito A, et al. Patient tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of glioblastoma multiforme. Neuro-oncol 2005;7:164-76.
3. Engebraaten O, Hjortland GO, Hirschberg H, Fodstad O. Growth of precultured human glioma specimens in nude rat brain. J Neurosurg1999;90:125-32.
4. Galli R, Binda E, Orfanelli U, et al. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res 2004;64:7011-21.
5. Gunther HS, Schmidt NO, Phillips HS, et al.Glioblastoma-derived stem cell-enriched cultures form distinct subgroups according to molecular and phenotypic criteria. Oncogene 2008;27:2897-909.
6. Frederick L, Wang XY, Eley G, James CD. Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res 2000; 60:1383-7.
7. Aldape KD, Ballman K, Furth A, et al. Immuno-histochemical detection of EGFRvIII in high malignancy grade astrocytomas and evaluation of prognostic significance. J Neuropathol Exp Neurol 2004;63:700-7.
8. Biernat W, Huang H,Yokoo H, Kleihues P, Ohgaki H. Predominant expression of mutant EGFR (EGFRvIII) is rare in primary glioblastomas. Brain Pathol 2004;14: 131-6.
9. Liu L, Backlund LM, Nilsson BR, et al. Clinical significance of EGFR amplification and the aberrant EGFR-vIII transcript in conventionally treated astrocytic gliomas. J Mol Med 2005;83:917-26.
10. Pelloski CE, Ballman KV, Furth AF, et al. Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma. J Clin Oncol 2007;25:2288-94.
11. Pandita A, Aldape KD, Zadeh G, Guha A, James CD. Contrasting in vivo and in vitro fates of glioblastoma cell subpopulations with amplified EGFR. GenesChro-mosomes Cancer 2004;39:29-36.
12. Lamszus K, Kunkel P,Westphal M. Invasion as limitation to anti-angiogenic glioma therapy. Acta Neurochir Suppl 2003;88:169-77.
13. Batchelor TT, Sorensen AG, di Tomaso E, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007;11:83-95.
14. Sathornsumetee S, Cao Y, Marcello JE, et al. Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan. J Clin Oncol 2008;26:271-8.
15. Lund-Johansen M, Bjerkvig R, Humphrey PA, Bigner SH, Bigner DD, Laerum OD. Effect of epidermal growth factor on glioma cell growth, migration, and invasion in vitro. Cancer Res 1990;50:6039-44.
16. Penar PL, Khoshyomn S, Bhushan A,TrittonTR. Inhibition of epidermal growth factor receptor-associated tyrosine kinase blocks glioblastoma invasion of the brain. Neurosurgery1997;40:141-51.
17. Lal A, Glazer CA, Martinson HM, et al. Mutantepi-dermal growth factor receptor up-regulates molecular effectors of tumor invasion. Cancer Res 2002;62:3335-9.
18. Brockmann MA, Ulbricht U, Gruner K, Fillbrandt R, Westphal M, Lamszus K. Glioblastoma and cerebral microvascular endothelial cell migration in response to tumor-associated growth factors. Neurosurgery 2003;52:1391-9.
19. Okada Y, Hurwitz EE, Esposito JM, Brower MA, Nutt CL, Louis DN. Selection pressures of TP53 mutation and microenvironmental location influence epidermal growth factor receptor gene amplification in human glioblastomas. Cancer Res 2003;63:413-6.
20. Bjerkvig R, Tonnesen A, Laerum OD, Backlund EO. Multicellular tumor spheroids from human gliomas maintained in organ culture. J Neurosurg 1990;72:463-75.
21. Rockwell P, Neufeld G, Glassman A, Caron D,Gold- stein N. In vitro neutralization of vascular endothelial growth factor activation of flk-1 by a monoclonal antibody.MolCellDiffer1995;3:91-109.
22. Goldstein NI, Prewett M, Zuklys K, Rockwell P, Mendelsohn J. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res 1995;1:1311-8.
23. Kunkel P, Ulbricht U, Bohlen P, et al. Inhibition ofglioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2. Cancer Res 2001;61:6624-8.
24. Haas-Kogan DA, Prados MD,TihanT, et al. Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J Natl Cancer Inst 2005;97:880-7.
25. Mellinghoff IK,Wang MY,Vivanco I, et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 2005;353:2012-24.
26. Choe G, Horvath S, CloughesyTF, et al. Analysis of the phosphatidylinositol 3′-kinase signaling pathway in glioblastoma patients in vivo. Cancer Res 2003;63:2742-6.
27. Neubauer A, Neubauer B, He M, et al. Analysis of gene amplification in archival tissue by differential polymerase chain reaction. Oncogene 1992;7:1019-25.
28. Ciardiello F. Epidermal growth factor receptor inhibitors in cancer treatment. Future Oncol 2005;1:221-34.
29. Goldman CK, Kim J, Wong WL, King V, Brock T, Gillespie GY. Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: a model of glioblastoma multiforme pathophysiology. Mol Biol Cell 1993;4:121-33.
30. Perrotte P, Matsumoto T, Inoue K, et al. Anti- epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin Cancer Res1999;5:257-65.
31. Karashima T, Sweeney P, Slaton JW, et al. Inhibition of angiogenesis by the antiepidermal growth factorreceptor antibody ImClone C225 in androgen-independent prostate cancer growing orthotopically in nude mice. Clin Cancer Res 2002;8:1253-64.
32. Sampson JH, Raghavan R, Brady ML, et al. Clinical utility of a patient-specific algorithm for simulating intracerebral drug infusions. Neuro-oncol 2007;9:343-53.
33. Sakariassen PO, Prestegarden L,Wang J, et al. Angiogenesis-independent tumor growth mediated by stem-like cancer cells. Proc Natl Acad Sci U S A 2006;103:16466-71.
34. Schiffer D, Chio A, Giordana MT, Mauro A, Migheli A, Vigliani MC. The vascular responseto tumor infiltration in malignant gliomas. Morphometric and reconstruction study. Acta Neuropathol 1989;77:369-78.
35. Wesseling P, van der Laak JA, de Leeuw H, Ruiter DJ, Burger PC. Quantitative immunohistological analysis of the microvasculature in untreated human glio- blastoma multiforme. Computer-assisted image analysis of whole-tumor sections. J Neurosurg 1994;81:902-9.
36. Eberhard A, Kahlert S, Goede V, Hemmerlein B, Plate KH, Augustin HG. Heterogeneity of angiogene- sis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. Cancer Res 2000;60:1388-93.
37. Nishikawa R, Ji XD, Harmon RC, et al. A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc Natl Acad Sci U S A1994;91:7727-31.
38. Patel D, Lahiji A, Patel S, et al. Monoclonal antibody cetuximab binds to and down-regulates constitutively activated epidermal growth factor receptor vIII on the cell surface. Anticancer Res 2007;27:3355-66.
39. Li S, Schmitz KR, Jeffrey PD, Wiltzius JJ, Kussie P, Ferguson KM. Structural basis forinhibition of theepi- dermal growth factor receptor by cetuximab. Cancer Cell 2005;7:301-11.
40. Kawamoto T, Sato JD, Le A, Polikoff J, Sato GH, Mendelsohn J. Growth stimulation of A431 cells by epidermal growth factor: identification of high-affinity receptors for epidermal growth factor by ananti- receptor monoclonal antibody. Proc Natl Acad Sci U S A1983;80:1337-41.
41. Luwor RB, Zhu HJ,Walker F, et al. The tumor-specific de2-7 epidermal growth factor receptor (EGFR) pro motes cells survival and heterodimerizes with the wild-type EGFR. Oncogene 2004;23:6095-104.
42. Johns TG, Perera RM,Vernes SC, et al. The efficacy of epidermal growth factor receptor-specific antibodies against glioma xenografts is influenced by receptor levels, activation status, and heterodimerization. Clin Cancer Res 2007;13:1911-25.
43. Learn CA, Hartzell TL,Wikstrand CJ, et al. Resistanceto tyrosine kinase inhibition by mutant epidermal growth factor receptor variant III contributes to the neoplastic phenotype of glioblastoma multiforme. Clin Cancer Res 2004;10:3216-24.
44. Rich JN, Reardon DA, PeeryT, et al. Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol 2004;22:133-42.
45. Sarkaria JN, Yang L, Grogan PT, et al. Identification of molecular characteristics correlated with glioblastoma sensitivity to EGFR kinase inhibition through use of an intracranial xenograft test panel. Mol Cancer Ther 2007;6:1167-74.
46. Eller JL, Longo SL, Hicklin DJ, Canute GW. Activity of anti-epidermal growth factor receptor monoclonal antibody C225 against glioblastoma multiforme. Neurosurgery 2002;51:1005-13.
47. Ermoian RP, Furniss CS, Lamborn KR, et al. Dysre- gulation of PTEN and protein kinase B is associated with glioma histologyand patient survival. Clin Cancer Res 2002;8:1100-6.
48. Lamszus K, Brockmann MA, Eckerich C, et al. Inhibition of glioblastoma angiogenesis and invasion by combined treatments directed against vascular endothelial growth factor receptor-2, epidermal growth factor receptor, and vascular endothelial-cadherin. Clin Cancer Res 2005;11:4934-40.